Abstract | BACKGROUND: METHODS: Adult, non-treatment seeking, MA-dependent volunteers (N=11) received oral placebo, moderate ibudilast (40 mg), and high-dose ibudilast (100mg) via twice-daily dosing for 7 days each in an inpatient setting. Following infusions of saline, MA 15 mg, and MA 30 mg participants rated 12 subjective drug effects on a visual analog scale (VAS). RESULTS: As demonstrated by statistically-significant ibudilast × MA condition interactions (p<.05), ibudilast reduced several MA-related subjective effects including High, Effect (i.e., any drug effect), Good, Stimulated and Like. The ibudilast-related reductions were most pronounced in the MA 30 mg infusions, with ibudilast 100mg significantly reducing Effect (97.5% CI [-12.54, -2.27]), High (97.5% CI [-12.01, -1.65]), and Good (97.5% CI [-11.20, -0.21]), compared to placebo. CONCLUSIONS:
Ibudilast appeared to reduce reward-related subjective effects of MA in this early-stage study, possibly due to altering the processes of neuroinflammation involved in MA reward. Given this novel mechanism of action and the absence of an efficacious medication for MA dependence, ibudilast warrants further study to evaluate its clinical efficacy.
|
Authors | Matthew J Worley, Aimee-Noelle Swanson, Keith G Heinzerling, Daniel J O Roche, Steve Shoptaw |
Journal | Drug and alcohol dependence
(Drug Alcohol Depend)
Vol. 162
Pg. 245-50
(05 01 2016)
ISSN: 1879-0046 [Electronic] Ireland |
PMID | 26993372
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
|
Copyright | Published by Elsevier Ireland Ltd. |
Chemical References |
- Pyridines
- Vasodilator Agents
- Methamphetamine
- ibudilast
|
Topics |
- Adult
- Amphetamine-Related Disorders
(drug therapy, psychology)
- Cross-Over Studies
- Double-Blind Method
- Female
- Humans
- Inpatients
- Male
- Methamphetamine
(antagonists & inhibitors)
- Middle Aged
- Pyridines
(pharmacology)
- Reward
- Self Administration
- Vasodilator Agents
(pharmacology)
|